Patients hospitalized for ACS were randomly assigned to standard of care or the pharmacogenomic arm, which included the genotyping of ABCB1, CYP2C19*2, and CYP2C19*17 using an ST Q3 system that provides data within 70 min at each patient's bedside.
The aim of this pilot prospective study was to evaluate 12-month cardiovascular outcomes in elderly patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy (aspirin and clopidogrel) according to the clustering of CYP2C19 and ABCB1 genetic variants.
We did not find evidence that the presence of <i>CYP2C19*2</i>, <i>CYP2C19*17</i>, and <i>ABCB1 3435</i> polymorphisms may jeopardize the safety of stent implantation in patients with an ACS.
Our findings provide empirical evidence that ABCB1C3435T polymorphism may contribute to the risk of MI and ACS, especially among Caucasian populations.
Our meta-analysis results indicated that ABCB1C3435T polymorphism may be associated with an increased risk of CHD, especially for MI and ACS among Caucasian populations.
We sought to assess the relationships between platelet reactivity at different time points, CYP2C19*2 and ABCB1 status and clinical outcomes in patients with acute coronary syndromes (ACS).